TrialNature communications2026

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306).

Harry H Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.